$1.50
-0.08 (-5.06%)
Open$1.56
Previous Close$1.58
Day High$1.57
Day Low$1.50
52W High$5.07
52W Low$0.99
Volume—
Avg Volume435.5K
Market Cap13.43M
P/E Ratio—
EPS$-1.14
SectorBiotechnology
Analyst Ratings
Buy
9 analysts
Price Target
+2,025.3% upside
Current
$1.50
$1.50
Target
$31.88
$31.88
$19.01
$31.88 avg
$45.37
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 183.4K | 866.6K | 5.21M |
| Net Income | -17,863,989 | -75,981,049 | -195,079 |
| Profit Margin | -9,756.5% | -9,268.7% | -3.8% |
| EBITDA | -19,454,561 | -87,343,255 | -244,954 |
| Free Cash Flow | — | — | -167,798 |
| Rev Growth | -78.8% | -78.8% | -0.3% |
| Debt/Equity | — | — | 1.55 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.35 | -1.10% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $419.87 | +0.42% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $150.65 | -1.02% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $525.69 | -0.38% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | +0.00% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $252.46 | -1.14% | 41.4 | 33.44B |